The Week in Blood Pressure & Wearables — August 14–21, 2026
Every week I go through the blood pressure and wearable health tech news that crosses my desk and pull out what actually matters to clinicians, RPM programs, and anyone trying to figure out where cuffless blood pressure and Medicare-funded remote monitoring are headed. This week the biggest story wasn't a new gadget. It was a wearable company backing a Medicare chronic-care benefit with a cuff, not a wrist sensor, and what that says about where the accuracy bar really sits.
Devices & Wearables
FDA clears Wellvii's finger-based blood pressure cuff. Wellvii's BP Go received FDA clearance this week as a compact, portable blood pressure monitor that measures blood pressure from the finger rather than the upper arm. Medical Economics covered the clearance, noting the company is positioning the device as a more convenient alternative to a traditional arm cuff for home use. This matters because it received 510(k) clearance as an actual blood pressure device, not as a wellness feature. That is a meaningfully different bar than most of what else launched this week.
Google's Health Guardian arrives on Pixel Watch 5, and it is explicitly not a blood pressure device. Google introduced Health Guardian alongside the Pixel Watch 5 on August 12, a suite of three new monthly trend summaries: blood pressure trends, insulin resistance trends, and sleep breathing quality. The label on all three is general wellness and informational only. Google is explicit that Health Guardian is not a pre-screener for diabetes, hypertension, or sleep apnea, does not provide real-time clinical readings, and should not be used to adjust medications or treatment plans. Google (through Fitbit) already holds FDA clearances for AFib detection and loss-of-pulse detection. It holds nothing on the blood pressure side, and neither do Apple or Samsung. No major consumer wearable maker currently has a cleared cuffless blood pressure product.
Johns Hopkins is testing wearable sensors and AI for continuous ICU blood pressure monitoring. A research effort out of Johns Hopkins is exploring whether wearable sensors paired with AI can provide ICU teams with continuous blood pressure readings without an arterial line, which carries its own risk of infection and complications. This is a genuinely different use case from consumer wellness wearables: a controlled clinical environment, a specific unmet need, and a clear bar for what "good enough" accuracy means when a missed spike could lead to a stroke or cardiac event.
Murj launches a remote patient monitoring platform for hypertension and heart failure.Murj announced a new RPM solution aimed at cardiovascular care teams managing patients with hypertension and heart failure, extending a platform historically built around cardiac implantable device data into broader remote monitoring. It is a small signal of a bigger pattern: platforms built for one corner of cardiac monitoring are expanding into hypertension because the reimbursement and clinical demand are both there.
Policy & Regulation
The story of the week: WHOOP built a Medicare chronic-care benefit around a cuff, not its own wrist sensor. On August 12, WHOOP launched Connected Care through WHOOP Physician Services, PC, live in 14 states and operating through CMS's new ACCESS Model. Eligible Original Medicare beneficiaries with at least one qualifying cardio-kidney-metabolic condition receive a 12-month WHOOP membership and an FDA-cleared blood pressure cuff, both at no out-of-pocket cost.
Read that again: the company gives beneficiaries an FDA-cleared cuff. Not a wrist-based blood pressure estimate. A cuff.
That detail is not incidental, and it is worth understanding the road that got WHOOP here. Earlier this year, WHOOP received an FDA warning letter over how it marketed a wrist-based blood pressure insight feature, drawing a line between what the company was implying the feature could do and what a general wellness product is legally allowed to claim. WHOOP adjusted the feature, and the FDA dropped its enforcement action in June. Two months later, when WHOOP built an actual Medicare-reimbursed chronic care benefit tied to real clinical outcomes, it didn't lean on the wrist feature that had just gotten it a warning letter. It bundled in a separately cleared cuff.
I have opinions about this because Cardiowell has been through the actual clearance process; this story keeps coming back up. We obtained FDA 510(k) clearance for our newest device, BT107, as a remote patient monitoring device for hypertension. That process is not a formality. It requires demonstrating measurement accuracy against a real reference standard, which is why a cuff-based reading can be trusted by a physician making a treatment decision, while a wrist-based optical estimate, however sophisticated the algorithm behind it, currently cannot.
What WHOOP's move tells me is that even a company with enormous engineering resources and one of the richest physiological datasets in consumer wearables looked at the actual clinical and reimbursement bar for hypertension RPM and concluded the honest path was to hand beneficiaries a cleared cuff rather than stretch its own sensor further than the FDA was willing to let it go. That is not a knock on WHOOP. It is validation of something small RPM companies like ours have believed since before it was fashionable to build a Medicare-facing product around wearables: for blood pressure specifically, the clinical bar and the wellness bar are not converging yet, and the companies moving fastest into reimbursed chronic care are the ones being honest about which side of that line their hardware sits on.
The bigger structural story here is the CMS ACCESS Model itself, a ten-year voluntary payment model that pays Medicare-enrolled providers for technology-supported chronic care with full payment contingent on hitting clinical outcome targets. It launched in July after drawing more than 150 applicants during its application window. This is the first large-scale federal mechanism built explicitly to fund the intersection of wearables, remote monitoring, and outcomes-based chronic care, and WHOOP will not be the last major wearable brand to build a product on top of it. Small hypertension-focused RPM companies should expect more competition from generalist platforms entering this exact reimbursement lane over the next year, and the ones that survive will be those who can point to the same kind of clearance and outcomes data that WHOOP just had to reach for.
The FDA also loosened its general wellness guidance this year, and it is worth knowing where that line actually sits.Coverage of the FDA's revised wellness device guidance describes a broader carve-out for non-medical-grade wearable and AI features, giving companies more room to ship informational health features without triggering device regulation. This is the regulatory backdrop that makes something like Health Guardian's wellness-only blood pressure trend feature possible without a clearance. It is a real and useful expansion for genuinely low-risk features. It is also exactly the kind of guidance that makes it easy to build a feature that looks like a clinical tool to an end user, even when the label says otherwise. The WHOOP story above is the clearest evidence yet of how that tension gets resolved once real money and real outcomes are on the line: wellness guidance gets you a feature, not a reimbursed benefit.
Dexcom becomes the FDA's first TEMPO pilot participant. The FDA named Dexcom the first participant in its TEMPO pilot, which allows certain digital health devices to be used without premarket authorization while real-world data is collected through CMS's ACCESS program, covering two ACCESS clinical use areas. TEMPO and ACCESS are meant to work together, one on the FDA side and one on the CMS side, to let outcomes data substitute for some of the traditional premarket burden. It is early, but it is a second concrete example this week of federal agencies building faster lanes for technology-supported chronic care, and RPM companies in hypertension should be watching for whether a similar pilot lane opens up in this category.
Clinical & Research
A new paper questions how much to trust published claims of cuffless blood pressure accuracy. A study on dataset integrity, calibration, and signal quality in neural network-based blood pressure estimation examined why cuffless blood pressure estimation using photoplethysmography and machine learning continues to report high accuracy in the literature despite the underlying reliability problems being widely known. The paper's framing, that reported accuracy remains questionable once dataset integrity, calibration approach, and signal quality are properly accounted for, is a useful corrective for anyone reading a cuffless BP accuracy claim at face value. This is the exact debate the WHOOP story above plays out in practice: publishable accuracy in a paper and clinically trustworthy accuracy in a Medicare-funded chronic care program are not the same bar.
Home blood pressure monitoring and follow-up should be a covered benefit, according to new cost-effectiveness research. An Annals of Internal Medicine study on how measurement error in systolic blood pressure affects the cost-effectiveness of intensive blood pressure treatment concluded that a concrete step for national insurers, including Medicare, would be to cover home blood pressure monitoring devices and structured follow-up to ensure treatment decisions are based on accurate readings. That is a direct, evidence-based case for the RPM billing structure hypertension programs are already built around, coming from a clinical journal rather than an industry source.
Intensive blood pressure lowering cut recurrent stroke risk by roughly 38 percent after brain hemorrhage. A study covered by EurekAlert found that intensive, long-term blood pressure-lowering treatment reduced the risk of recurrent stroke by about 38 percent without increasing serious adverse events in patients who had already had a brain hemorrhage. It is a reminder that the clinical stakes behind all of this reimbursement and device news are not abstract. Getting blood pressure control right and consistent after a serious cardiovascular event has a large, measurable effect on whether it happens again.
Community health centers are getting direct support to build self-measured blood pressure monitoring programs.JSI and Arbor Research announced a partnership to support hypertension care through self-measured blood pressure monitoring at community health centers, citing the more than 660,000 annual deaths in which high blood pressure is a contributing factor. It is a smaller story than the CMS and FDA news above, but it is a useful reminder that self-measured blood pressure monitoring, done well, is already a proven intervention independent of any wearable or AI layer on top of it.
Also worth a glance
Abbott and Google Health announced a multi-year partnership on August 11, piping glucose data from Abbott's over-the-counter Lingo continuous glucose monitor into the Google Health app alongside sleep, activity, and heart data, with Google's Health Coach turning it into guidance. Eli Lilly took an undisclosed equity position in Oura on July 15, following a LillyDirect collaboration that gives GLP-1 customers a complimentary Oura sizing kit. Both are covered in more detail in Blythe Karow's roundup at The Device Files, which is worth a subscribe if you want the wider wearables and MedTech commercialization picture this column doesn't always have room for.
The thread connecting all of it
Pull back from the individual stories and one thread runs through nearly all of them: the wellness-versus-medical-device line in blood pressure technology isn't blurring; it's getting sharper, and the money is what's sharpening it. Google ships blood pressure trends labeled strictly as wellness. A new paper questions whether cuffless accuracy claims hold up under real scrutiny. And when a wearable company with real engineering muscle had to build an actual Medicare-reimbursed chronic care benefit, it reached for a cleared cuff rather than its own sensor. Meanwhile, the clinical literature keeps making the same point from a different angle: measurement accuracy drives real outcomes, and covering home blood pressure monitoring and structured follow-up is a defensible policy position, not just an industry talking point. If you're building or evaluating anything in this space right now, that is the question worth asking about every new product: is this cleared to be trusted with a treatment decision, or is it cleared to be trusted with a trend line? This week made it clear that those are still two very different products.